TuesdayMay 05, 2026 10:00 am

Immunologists Discover How Cancer Reprograms Immune Cells to Support Cancer Growth

Immunotherapy has emerged as a key weapon in the fight against cancer. However, nearly 80% of patients either don’t respond to these treatments or they become unresponsive after initially responding to the immunotherapy. The scientific community has been grappling with how to improve response rates, and a new study uncovering how cancer cells reprogram our immune cells to support cancer growth could provide a key.  The study, whose findings were published in Science Immunology, was conducted by a team at the University of Texas at Dallas. The team found that cancer doesn’t just hide from immune cells. Rather, it actively reprograms the immune cells within the tumor microenvironment so that they become suppressed and cannot mount an attack against…

Continue Reading

TuesdayMay 05, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions

Cardiovascular disease remains the leading cause of death in the United States. One of the most persistent challenges in cardiac care is patient delay in seeking care. HeartBeam is working to address this gap by transforming how ECG data are collected and used through its HeartBeam System. Cardiovascular disease continues to be a major global health challenge, driven by aging populations, lifestyle factors and persistent gaps in early detection that continue to challenge healthcare systems. In response to these trends, HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising…

Continue Reading

FridayMay 01, 2026 10:30 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

The scale and consequences of cardiovascular disease reinforce why innovation in this space remains essential. The prevalence of cardiovascular risk factors illustrates the scale of the issue. Cardio Diagnostics is addressing this need through its proprietary platform, which combines artificial intelligence with multi-omic biomarker analysis. Cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide, affecting millions of lives while driving substantial medical costs and resource demands. Cardio Diagnostics Holdings (NASDAQ: CDIO) is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized…

Continue Reading

FridayMay 01, 2026 10:00 am

Study Uncovers Why the Risk of Breast Cancer Increases with Age

New research has mapped how breast tissues change as women age. The findings help to explain why breast cancer cases are higher in older women, and this could potentially help in finding new ways to fight this disease.  The study, which appeared in Nature Aging, was conducted by a team from the UK-based University of Cambridge and the Canada-based University of British Columbia, and they created a map that covered at least 3 million breast tissue cells. This is the most extensive such map so far available.  The map revealed how these breast tissues change as someone ages, and they found an especially notable shift coinciding with menopause.  The study’s joint first…

Continue Reading

ThursdayApr 30, 2026 10:00 am

House Hearing Puts Hospital CEOs on the Spot Over Exorbitant Charges

During a recent House hearing conducted by the Ways and Means Committee, hospital CEOs were put on the spot over the inexplicably high facility fees that they charge. GOP members of the committee accused the hospitals of taking advantage of the healthcare system and of overcharging patients.  The hospital executives who attended the hearing included those from CommonSpirit Health, HCA Healthcare, ECU Health and New York Presbyterian.  Approximately $1.6 trillion of the money spent on healthcare in 2024 went to hospitals, and this was approximately 33% of the total amount that went to healthcare in that year. The executives asserted that it was within their rights to levy higher fees when…

Continue Reading

TuesdayApr 28, 2026 10:00 am

Study Finds Exercise, Ibuprofen Combat Brain Fog in Cancer Patients

Most cancer patients report cognitive deterioration, such as memory loss and difficulty concentrating as they undergo cancer treatments like chemotherapy and radiation. This has widely come to be known as “chemo brain.” Recent research suggests that exercising and taking a common OTC drug, ibuprofen, can alleviate these cognitive effects of cancer therapy. The study, which was conducted by a team at University of Rochester Medical Center, was led by Prof. Michelle Janelsins. The team recruited 86 patients undergoing cancer treatment and divided them into four groups during this Phase 2 clinical study. One group did exercises designed for cancer patients…

Continue Reading

TuesdayApr 28, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Deploying AI for Non-Invasive Intoxication Detection

Voice Analytics and AI to Transform Drug and Alcohol Testing Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising. MindBio Therapeutics is developing AI-driven voice analysis technology to detect drug and alcohol impairment without relying on invasive and time-consuming breath, saliva, or laboratory testing. The company’s platform analyzes more than 140 acoustic markers and is trained on over 50 million data points to estimate intoxication levels from short voice samples. The new technology is seen applicable to both workplace and non-workplace settings, with the global alcohol and drug testing devices market projected to grow from…

Continue Reading

TuesdayApr 28, 2026 9:00 am

The Evidence-Interrogation Play: How Oncotelic Therapeutics Inc.’s (OTLC) PDAOAI Platform Fits Pharma’s Broader AI Transformation

Oncotelic’s PDAOAI platform indexes 125,000+ PubMed abstracts on TGF-β signaling, enabling researchers to interrogate the evidence for testable, auditable hypotheses rather than rely on black-box predictions. Recent industry coverage places Oncotelic alongside Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s shift toward AI-integrated operations. The hypothesis-first approach addresses a core challenge in biotech research: reducing training-set bias and building transparent, reproducible chains from question to evidence to hypothesis. Pharmaceutical research and manufacturing are undergoing a structural transition. Regulatory agencies are raising expectations around data integrity and traceability, while the industry is shifting from…

Continue Reading

MondayApr 27, 2026 9:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing AI Solutions for Cardiovascular Disease Detection and Management

The scale and impact of cardiovascular disease underscore why innovation in this area is so critical. Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression. By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing. Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic…

Continue Reading

FridayApr 24, 2026 11:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) AI Platform Brings Precision to Heart Health

At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate multi-omic data to provide a more comprehensive view of cardiovascular health. The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk. CDIO’s focus on accessibility and scalability is also notable. Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a proprietary…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000